Myostatin Proform human

MSTN (myostatin) belongs to the transforming growth factor-β (TGF β) superfamily containing numerable homologous cytokine proteins. This gene is expressed in skeletal muscle, and codes for a precursor protein composed of an N-terminal leader peptide, a pro-peptide domain, and a C-terminal domain. This precursor protein is proteolytically cleaved by bone morphogenetic protein 1 (BMP-1) at a conserved four amino acid RSRR site to produce the 13kDa mature protein.

MSTN (myostatin) functions as a negative modulator of muscle cell development. It functions through forming heteromeric receptor complexes such as with activin type II receptor B (ActRIIB), and with lesser affinity with ActIIA. This interaction results in the recruitment of type I receptors like activin receptor-like kinase 4 (ALK4) or ALK5, leading to the phosphorylation of Smad2 (small mothers against decapentaplegic) and Smad3, which move to the nucleus and suppress myogenesis. In MSTN-null mice, there is delayed skin wound healing due to the increased expression of decorin, an endogenous transforming growth factor-β (TGF β) suppressor. Topical treatment with TGF-β1 restored skin wound healing, suggesting that MSTN agonists might have therapeutic beneficial in skin wound repair.

Lyophilized without any additives.

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Reconstitute in water to a concentration of 0.1 to 1.0 mg/mL. This solution can then be diluted into other aqueous buffers.